Tempus AI (TEM) said Tuesday that its artificial intelligence-enabled care pathway intelligence platform will now support breast cancer patients.
The company said Tempus Next now addresses five testing gaps tied to breast cancer biomarkers and has been integrated into electronic medical records at Mercy, a provider network.
Tempus said the breast cancer expansion was funded by the company and one or more life sciences sponsors.
Shares of the company were up 1.8% in recent early trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.